 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
News Briefs In Brief: DrugsApril 17, 2002 Pfizer will freeze the price of its AIDS drug, Viracept, for the next two years for the federal AIDS Drug Assistance Program (ADAP), according to CEO Hank McKinnell. McKinnell made the announcement at the first meeting of the President's Advisory Council on HIV/AIDS, to which he was appointed in late February. ADAP has waiting lists in 10 states and territories, and has seen its funding threatened on a national level as well. The protease inhibitor is among the best-selling medications in its class, making up more than 35 percent of protease sales in 2000. The current wholesale price for Viracept is $2.02 per tablet. Dosage is five tablets twice a day. AIDS Policy & Law 04.12.02  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
